Anion gap high is a condition that occurs when the levels of certain electrolytes in the bloodstream are out of balance. It is a common laboratory finding that can be indicative of a variety of underlying metabolic abnormalities. Anion gap high is also known as hyperchloremic metabolic acidosis or hyperchloremic acidosis. In this article, we will take a closer look at the link between metabolic abnormalities and anion gap elevations, and discuss the various causes of anion gap high.
An anion gap is a measure of the difference between the concentrations of certain electrolytes in the bloodstream. It is calculated by subtracting the concentrations of the major anions (chloride and bicarbonate) from the concentrations of the major cations (sodium and potassium). A normal anion gap is typically between 8 and 12 mmol/L. An elevated anion gap indicates that there is an imbalance between the concentrations of electrolytes in the blood.
Anion gap high can be caused by a variety of metabolic abnormalities. These abnormalities can be divided into three main categories: renal tubular acidosis, metabolic acidosis, and hyperchloremic acidosis.
Renal tubular acidosis (RTA) is a condition in which the kidneys are unable to excrete acid properly. This leads to an accumulation of acid in the bloodstream, which can cause anion gap high. RTA can be caused by a variety of conditions, including certain medications, chronic kidney disease, and inherited genetic disorders.
Metabolic acidosis is a condition in which the body produces too much acid, or is unable to effectively eliminate acid from the bloodstream. This can lead to anion gap high. Metabolic acidosis can be caused by a variety of underlying conditions, including diabetes, liver disease, and kidney failure.
Hyperchloremic acidosis is a condition in which the body produces too much chloride, or is unable to effectively eliminate chloride from the bloodstream. This can lead to anion gap high. Hyperchloremic acidosis can be caused by a variety of underlying conditions, including dehydration, certain medications, and certain medical procedures.
Anion gap high can be indicative of a variety of underlying conditions, and it is important for healthcare providers to be aware of the potential causes of anion gap high. An elevated anion gap can be a sign of metabolic acidosis, which can lead to a variety of serious complications, including kidney failure and coma. It is also important to note that anion gap high can be caused by a variety of conditions, and it is important to identify the underlying cause of the elevation in order to provide the most effective treatment.
Anion gap high is a common laboratory finding that can be indicative of a variety of underlying metabolic abnormalities. These abnormalities can be divided into three main categories: renal tubular acidosis, metabolic acidosis, and hyperchloremic acidosis. It is important for healthcare providers to be aware of the potential causes of anion gap high, as it can be indicative of a variety of serious conditions. Identifying the underlying cause of the elevation is essential in order to provide the most effective treatment.
1.
Breast Cancer Patients Living Longer Post-Medicaid Expansion
2.
Error on the MGUS-Autoimmune Disease Association.
3.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
4.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
5.
Unified Neuro/Psych Residency Program: New Proposal.
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
3.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
4.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
5.
The Growing Challenge of Haematological Malignancies in Older Adults
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation